ライフサイエンスコーパス: heart-lung

1 The availability of suitable lung and heart-lung allografts for transplantation remains poor.

2 Lung and heart-lung allografts from HBcAb positive donors may be

3 pose of this study is to review the National Heart Lung and Blood Institute (NHBLI) guidelines on scr

4 g from National Institute of Health/National Heart Lung and Blood Institute career development grants

5 a limited-access database from the National Heart Lung and Blood Institute's Viral Activation Transf

6 National Cancer Institute, National Heart Lung and Blood Institute, National Institute for A

7 ty Executive, Department of Health, National Heart Lung and Blood Institute, National Institute on Ag

8 US National Heart Lung and Blood Institute, US National Institute of

9 cutive, UK Department of Health, US National Heart Lung and Blood Institute, US National Institute on

10 National Institute on Aging, National Heart Lung and Blood Institute.

11 nstitutes of Health (NIH) including National Heart, Lung and Blood Institute (NHLBI), the National In

12 asthma treatment and monitoring per National Heart, Lung and Blood Institute asthma guidelines.

13 National Heart, Lung and Blood Institute Division of Intramural R

14 xamined the exome data set from the National Heart, Lung and Blood Institute Exome Sequencing Project

15 The National Heart, Lung and Blood Institute of the National Institut

16 African American subjects from the National Heart, Lung and Blood Institute's Family Blood Pressure

17 National Heart, Lung and Blood Institute, National Institutes of

18 The phase 3 National Heart, Lung and Blood Institute-sponsored Multicenter St

19 As part of the National Heart, Lung and Blood Institute-sponsored WISE (Women's

20 National Heart, Lung and Blood Institute.

21 American Heart Association and the National Heart, Lung and Blood Institute.

22 National Heart, Lung and Blood Institute; Johns Hopkins Institute

23 titute of General Medical Sciences; National Heart, Lung And Blood Institute; National Human Genome R

24 t is expressed in multiple tissues including heart, lung and brain.

25 nically stressed dynamic tissues such as the heart, lungs and tendons.

26 ortedly causing major adverse effects on the heart, lungs and the brain.

27 l decellularization of complex organs (i.e., hearts, lungs and kidneys) can be performed.

28 ealed the role of miR-17 approximately 92 in heart, lung, and B-cell development and in Myc-induced B

29 With the growing burden of HIV-related heart, lung, and blood (HLB) disease, the National Heart

30 with making recommendations to the National Heart, Lung, and Blood Advisory Council about how the Na

31 matrix mechanics, which we illustrate across heart, lung, and blood development.

32 orking Group, Advancing HIV/AIDS Research in Heart, Lung, and Blood Diseases, charged with identifyin

33 y matched control subjects from the National Heart, Lung, and Blood Grand Opportunity Exome Sequencin

34 National Heart, Lung, and Blood Institute (1R01HL108441-01A1) and

35 ation (Geneva, Switzerland) and the National Heart, Lung, and Blood Institute (Bethesda, Maryland) ha

36 The FOA Study was funded by the National Heart, Lung, and Blood Institute (for the parent Framing

37 in HCM has been highlighted by the National Heart, Lung, and Blood Institute (NHLBI) as a research p

38 iovascular R01 grants funded by the National Heart, Lung, and Blood Institute (NHLBI) between 1980 an

39 For these reasons, the National Heart, Lung, and Blood Institute (NHLBI) convened a work

40 through lung disease research, the National Heart, Lung, and Blood Institute (NHLBI) convened a work

41 The National Heart, Lung, and Blood Institute (NHLBI) convened a Work

42 The National Heart, Lung, and Blood Institute (NHLBI) convened a work

43 s (TCGA), the 1000 Genomes Project, National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencin

44 As part of the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencin

45 The National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencin

46 n Genome Research Institute (NHGRI)/National Heart, Lung, and Blood Institute (NHLBI) grant U54HG0065

47 The National Heart, Lung, and Blood Institute (NHLBI) has been closel

48 The National Heart, Lung, and Blood Institute (NHLBI) of the National

49 scribes programmes supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National

50 The National Heart, Lung, and Blood Institute (NHLBI) of the National

51 lung, and blood (HLB) disease, the National Heart, Lung, and Blood Institute (NHLBI) recognizes it m

52 US National Heart, Lung, and Blood Institute (NHLBI), and The Cowlin

53 This paper describes ongoing National, Heart, Lung, and Blood Institute (NHLBI)-initiated child

54 ventions that were supported by the National Heart, Lung, and Blood Institute (NHLBI).

55 National Heart, Lung, and Blood Institute (US National Institutes

56 had evolved in the decade since the National Heart, Lung, and Blood Institute 2004 working group repo

57 mples from subjects enrolled in two National Heart, Lung, and Blood Institute Acute Respiratory Distr

58 ngham Heart Study, a project of the National Heart, Lung, and Blood Institute and Boston University t

59 National Heart, Lung, and Blood Institute and European Union Seve

60 Merck & Co. and the National Heart, Lung, and Blood Institute and National Cancer Ins

61 US National Heart, Lung, and Blood Institute and National Cancer Ins

62 National Heart, Lung, and Blood Institute and National Institute

63 oundation; Bupa Foundation; and the National Heart, Lung, and Blood Institute and National Institute

64 National Heart, Lung, and Blood Institute and National Institute

65 The National Heart, Lung, and Blood Institute and Office of Rare Dise

66 in Children and Adolescents of the National Heart, Lung, and Blood Institute and the 2013 Guideline

67 The National Heart, Lung, and Blood Institute and the Adult Congenita

68 d at 2 workshops cosponsored by the National Heart, Lung, and Blood Institute and the American Societ

69 The US National Heart, Lung, and Blood Institute and the European Societ

70 US National Heart, Lung, and Blood Institute and the National Cancer

71 Intramural Research Program of the National Heart, Lung, and Blood Institute and the National Cancer

72 National Heart, Lung, and Blood Institute and the National Center

73 National Heart, Lung, and Blood Institute and UnitedHealth Group.

74 e Institutional Review Board of the National Heart, Lung, and Blood Institute and was funded by the N

75 In 2008, the National Heart, Lung, and Blood Institute announced its intent to

76 al nutrition at 44 hospitals in the National Heart, Lung, and Blood Institute ARDS Clinical Trials Ne

77 al nutrition at 44 hospitals in the National Heart, Lung, and Blood Institute ARDS Clinical Trials Ne

78 In 2013, the National Heart, Lung, and Blood Institute assembled a working gro

79 The National Heart, Lung, and Blood Institute AsthmaNet consortium ha

80 European-American samples from the National Heart, Lung, and Blood Institute Candidate Gene Associat

81 The National Heart, Lung, and Blood Institute closed SWiTCH after int

82 nts in a conference convened by the National Heart, Lung, and Blood Institute concluded that a signif

83 rts, as well as those from a recent National Heart, Lung, and Blood Institute consensus conference, s

84 how population studies supported by National Heart, Lung, and Blood Institute contracts might be stra

85 On October 1 and 2, 2015, the National Heart, Lung, and Blood Institute convened a group of ext

86 The National, Heart, Lung, and Blood Institute convened a Think Tank m

87 The National Heart, Lung, and Blood Institute convened a working grou

88 In December 2011, the National Heart, Lung, and Blood Institute convened a workshop to

89 he Division of Lung Diseases in the National Heart, Lung, and Blood Institute convened a workshop, "G

90 The National Heart, Lung, and Blood Institute convened an expert pane

91 In 2008, the National Heart, Lung, and Blood Institute convened an Implementat

92 In 2008, the National Heart, Lung, and Blood Institute convened the Adult Trea

93 lood Advisory Council about how the National Heart, Lung, and Blood Institute could take advantage of

94 rding to American Heart Association/National Heart, Lung, and Blood Institute criteria and included a

95 ometrics to describe the use of the National Heart, Lung, and Blood Institute data repository.

96 current American Heart Association/National Heart, Lung, and Blood Institute definition for adults (

97 yzed data from 6551 patients in the National Heart, Lung, and Blood Institute Dynamic Registry accord

98 Patients in the National Heart, Lung, and Blood Institute Dynamic Registry enroll

99 Using the National Heart, Lung, and Blood Institute Dynamic Registry, we ev

100 4,313 European Americans) from the National Heart, Lung, and Blood Institute Exome Sequencing Projec

101 icipants randomly selected from the National Heart, Lung, and Blood Institute Exome Sequencing Projec

102 through simulation studies and the National Heart, Lung, and Blood Institute Exome Sequencing Projec

103 In the National Heart, Lung, and Blood Institute Exome Sequencing Projec

104 injury exome-sequencing data of the National Heart, Lung, and Blood Institute Exome Sequencing Projec

105 trols; LifePool, 2010 controls; and National Heart, Lung, and Blood Institute Exome Sequencing Projec

106 d CAC in 2703 participants from the National Heart, Lung, and Blood Institute Family Heart Study who

107 also details recommendations to the National Heart, Lung, and Blood Institute for a new framework for

108 The National Heart, Lung, and Blood Institute funded 3 centers and a

109 789 Marfan patients enrolled in the National Heart, Lung, and Blood Institute GenTAC (Genetically Tri

110 encies in OC were compared with the National Heart, Lung, and Blood Institute GO Exome Sequencing Pro

111 National Heart, Lung, and Blood Institute guideline-adherent (mac

112 lled asthma, as defined by the 2007 National Heart, Lung, and Blood Institute guidelines' impairment

113 3 or step 4 combination therapy per National Heart, Lung, and Blood Institute guidelines, received IC

114 y poorly controlled asthma based on National Heart, Lung, and Blood Institute guidelines.

115 The National Heart, Lung, and Blood Institute has a strong interest i

116 tional Institutes of Health and the National Heart, Lung, and Blood Institute have developed new appr

117 ardiovascular RCTs sponsored by the National Heart, Lung, and Blood Institute have substantial rates

118 s in 5 cohorts participating in the National Heart, Lung, and Blood Institute HIV-CVD Collaborative t

119 sing from a meeting convened by the National Heart, Lung, and Blood Institute in August 2009, to asse

120 novo (type 1) R01 grants funded by National Heart, Lung, and Blood Institute in fiscal year 2009: th

121 Although the National Heart, Lung, and Blood Institute increased funding of ca

122 cent National Institutes of Health, National Heart, Lung, and Blood Institute initiative on integrati

123 Senior program staff at the National Heart, Lung, and Blood Institute invite the epidemiology

124 The National Heart, Lung, and Blood Institute longitudinal cohort stu

125 uestions of treatment and care, the National Heart, Lung, and Blood Institute of the National Institu

126 The National Heart, Lung, and Blood Institute of the National Institu

127 The National Institutes of Health/National Heart, Lung, and Blood Institute Pediatric Heart Network

128 Data consisted of accessing National Heart, Lung, and Blood Institute public information, dat

129 1492 investigator-initiated de novo National Heart, Lung, and Blood Institute R01 grant applications

130 In 2006, the National Heart, Lung, and Blood Institute released a funding oppo

131 As funders of research, we at the National Heart, Lung, and Blood Institute seek to support project

132 The National Heart, Lung, and Blood Institute Severe Asthma Research

133 Recognizing this void, the National Heart, Lung, and Blood Institute solicited proposals for

134 p summary from a recently conducted National Heart, Lung, and Blood Institute strategic planning work

135 lowed up to 2010 in the prospective National Heart, Lung, and Blood Institute Twin Study.

136 were identified for review from the National Heart, Lung, and Blood Institute website and the biomedi

137 The overarching purpose of the National Heart, Lung, and Blood Institute workshop on "Malformed

138 An Executive Summary of a National Heart, Lung, and Blood Institute workshop on this topic

139 Furthermore, a survey of the National Heart, Lung, and Blood Institute's (NHLBI's) Exome Seque

140 o assure the Blood community of the National Heart, Lung, and Blood Institute's (NHLBI) commitment to

141 mericans and 471 Europeans from the National Heart, Lung, and Blood Institute's (NHLBI) Exome Sequenc

142 the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Resea

143 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, wi

144 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, wi

145 ancestry participants from CHARGE, National Heart, Lung, and Blood Institute's Exome Sequencing Proj

146 xomes of >5000 individuals from the National Heart, Lung, and Blood Institute's Exome Sequencing Proj

147 The National Heart, Lung, and Blood Institute's Growth and Health Stu

148 s who attended examination 2 of the National Heart, Lung, and Blood Institute's Multi-Ethnic Study of

149 patient and clinician uptake of the National Heart, Lung, and Blood Institute's National Asthma Educa

150 The National Heart, Lung, and Blood Institute's Next Generation Genet

151 d access database obtained from the National Heart, Lung, and Blood Institute's Viral Activation Tran

152 e National Heart Institute (now the National Heart, Lung, and Blood Institute) in its very early days

153 n with interested parties (from the National Heart, Lung, and Blood Institute, American Heart Associa

154 Digestive and Kidney Diseases, the National Heart, Lung, and Blood Institute, and the American Diabe

155 National Heart, Lung, and Blood Institute, and the COPD Foundatio

156 m the Food and Drug Administration, National Heart, Lung, and Blood Institute, Centers for Medicare a

157 ion, American Heart Association, US National Heart, Lung, and Blood Institute, Columbia University, H

158 US National Heart, Lung, and Blood Institute, National Center for Ad

159 National Heart, Lung, and Blood Institute, National Institute of

160 Intramural Research Program, National Heart, Lung, and Blood Institute, National Institutes of

161 National Heart, Lung, and Blood Institute, National Institutes of

162 National Heart, Lung, and Blood Institute, National Institutes of

163 The National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute

164 The National Heart, Lung, and Blood Institute, through a request for

165 US National Heart, Lung, and Blood Institute, US National Center for

166 With support from the National Heart, Lung, and Blood Institute, we established the Con

167 tissue engineering programs of the National Heart, Lung, and Blood Institute, which support research

168 is hypothesis, we have launched the National Heart, Lung, and Blood Institute- and National Human Gen

169 moking and current SHS exposures on National Heart, Lung, and Blood Institute-defined asthma control.

170 data from 1964 through 2008 from 5 National Heart, Lung, and Blood Institute-funded community-based

171 The National Heart, Lung, and Blood Institute-funded Pediatric Cardia

172 hildren with FDCM or IDCM using the National Heart, Lung, and Blood Institute-funded Pediatric Cardio

173 icle highlights several examples of National Heart, Lung, and Blood Institute-initiated translational

174 in clinical trials conducted by the National Heart, Lung, and Blood Institute-sponsored Asthma Clinic

175 eiving maximal medical therapy at 5 National Heart, Lung, and Blood Institute-sponsored Cardiovascula

176 -controlled trial (LateTIME) of the National Heart, Lung, and Blood Institute-sponsored Cardiovascula

177 -release and internal datasets from National Heart, Lung, and Blood Institute-sponsored cohorts, we e

178 and between races in 3 multicenter, National Heart, Lung, and Blood Institute-sponsored cohorts.

179 lly Assisted Circulatory Support, a National Heart, Lung, and Blood Institute-sponsored collaboration

180 is a large, predominantly biracial, National Heart, Lung, and Blood Institute-sponsored epidemiologic

181 exercise capacity, conducted in the National Heart, Lung, and Blood Institute-sponsored Heart Failure

182 Genomic DNAs from 223 subjects of 2 National Heart, Lung, and Blood Institute-sponsored randomized cl

183 jected With ALDH Bright Cells) is a National Heart, Lung, and Blood Institute-sponsored, randomized,

184 ity measures included the number of National Heart, Lung, and Blood Institute-supported publications

185 alth and Human Development, and the National Heart, Lung, and Blood Institute.

186 National Heart, Lung, and Blood Institute.

187 The National Heart, Lung, and Blood Institute.

188 l treatment trials performed by the National Heart, Lung, and Blood Institute.

189 nd ALVEOLI trial), sponsored by the National Heart, Lung, and Blood Institute.

190 National Heart, Lung, and Blood Institute.

191 iovascular outcomes research by the National Heart, Lung, and Blood Institute.

192 National Heart, Lung, and Blood Institute.

193 or Medicare & Medicaid Services and National Heart, Lung, and Blood Institute.

194 y Research Network sponsored by the National Heart, Lung, and Blood Institute.

195 PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute.

196 ure in the Hematology Branch of the National Heart, Lung, and Blood Institute.

197 V cardiovascular RCTs funded by the National Heart, Lung, and Blood Institute.

198 National Institute on Aging and US National Heart, Lung, and Blood Institute.

199 National Institutes of Health-National Heart, Lung, and Blood Institute.

200 National Heart, Lung, and Blood Institute.

201 ram, National Institutes of Health, National Heart, Lung, and Blood Institute.

202 American Heart Association and the National Heart, Lung, and Blood Institute.

203 Healthcare Research and Quality and National Heart, Lung, and Blood Institute.

204 National Heart, Lung, and Blood Institute.

205 are conducted and supported by the National Heart, Lung, and Blood Institute.

206 This trial was funded by the National Heart, Lung, and Blood Institute.

207 ce: National Institute on Aging and National Heart, Lung, and Blood Institute.

208 review originally initiated by the National Heart, Lung, and Blood Institute.

209 National Heart, Lung, and Blood Institute.

210 US National Heart, Lung, and Blood Institute/National Institutes of

211 Texas Southwestern Medical Center; National Heart, Lung, and Blood Institute; and American Heart Ass

212 National Institute on Aging; National Heart, Lung, and Blood Institute; and Massachusetts Gene

213 e of Environmental Health Sciences; National Heart, Lung, and Blood Institute; and Merck Childhood As

214 e NIH Office of Disease Prevention; National Heart, Lung, and Blood Institute; and National Institute

215 or Healthcare Research and Quality; National Heart, Lung, and Blood Institute; and Society of Critica

216 The US National Heart, Lung, and Blood Institute; and the National Insti

217 US National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of

218 National Institutes of Health and National Heart, Lung, and Blood Institute; National Institute on

219 National Institutes of Health; National Heart, Lung, and Blood Institute; Pulmonary Fibrosis Fou

220 US National Heart, Lung, and Blood Institute; the Alpha-1 Foundation

221 US National Heart, Lung, and Blood Institute; Wyeth.

222 convened a Working Group to address emerging heart, lung, and blood research priorities related to HI

223 causing multiple abnormalities in the liver, heart, lung, and blood vessels.

224 gulator across several organs, including the heart, lung, and brain, suggesting that it is a fundamen

225 nd several adult mouse tissues including the heart, lung, and brain.

226 ssues including kidney, pancreas, intestine, heart, lung, and brain.

227 al contractile and relaxation motions of the heart, lung, and diaphragm, demonstrated in several diff

228 nterstitial and perivascular fibrosis in the heart, lung, and kidney as a result of enhanced myofibro

229 rdependent feedback mechanisms involving the heart, lung, and kidney.

230 All surviving heart, lung, and liver transplant patients from Auckland

231 and kidney transplantations and one combined heart, lung, and liver transplantations.

232 eral different tissues, including the brain, heart, lung, and liver.

233 these conditions included asthma; diabetes; heart, lung, and neurologic diseases; and pregnancy.

234 ipients from 2000 to 2008 for liver, kidney, heart, lung, and simultaneous pancreas/kidney transplant

235 in cases of kidney, liver, bowel, pancreas, heart, lung, and stem-cell transplant, and blood transfu

236 on but also during normal development of the heart, lungs, and immune system.

237 solitary tract nucleus (NTS) to control the heart, lungs, and other vital organs.

238 rphogenesis of asymmetric organs such as the heart, lungs, and stomach.

239 ted States reads CT screening studies of the heart, lungs, and whole body and holds favorable attitud

240 tudies (30 kidney, 18 liver, 8 heart, 2 lung/heart-lung, and 3 with mixed recipient samples) were inc

241 idney-pancreas, 7.3% small bowel/liver, 5.7% heart/lung, and 3.3% multivisceral.

242 Rat heart-lung blocks were placed on EVLP for 4 hours with o

243 by the American Heart Association / National Heart Lung Blood Institute criteria (HR, 0.63; 95% CI, 0

244 pproximately 50 000 SNPs from 2000 candidate heart, lung, blood and sleep genes.

245 ilding on the track record of success of the heart, lung, blood, and sleep cohorts to leverage new da

246 te future directions for the epidemiology of heart, lung, blood, and sleep diseases.

247 s in population sciences and epidemiology of heart, lung, blood, and sleep diseases; 2) developing me

248 r new understanding of nature's solutions to heart, lung, blood, and sleep disorders through future r

249 strong foundation for the transformation of heart, lung, blood, and sleep epidemiology.

250 iR-92 were evaluated in five canine tissues (heart, lung, brain, kidney, and liver) using the delta-d

251 ould inform prevention strategies for common heart-lung conditions.

252 raniofacial skeleton, ear, branchial arches, heart, lungs, diaphragm, gut, kidneys, and gonads.

253 Region Vastra Gotaland, Sweden), the Swedish Heart-Lung Foundation, Diabetes Wellness, Novo Nordisk F

254 Swedish Heart-Lung Foundation, Swedish Research Council, Austral

255 Swedish Research Council, Swedish Heart-Lung Foundation, Swedish Society for Medical Resea

256 ource: The Swedish Research Council, Swedish Heart-Lung Foundation, Swedish Society for Medical Resea

257 on of Local Authorities and Regions, Swedish Heart-Lung Foundation.

258 ch Council of Norway, AFA Insurance, Swedish Heart Lung Fund, Foundation of Marianne and Marcus Walle

259 rvate the majority of visceral organs (e.g., heart, lungs, GI tract, etc) and their activation is cri

260 Our findings underscore the complexity of heart-lung interaction in determining pulmonary hemodyna

261 cluding engineered models of diseases of the heart, lung, intestine, liver, kidney, cartilage, skin a

262 rgan status (for a liver in combination with heart, lung, intestine, or pancreas) and then on a natio

263 The end points analyzed included death and heart, lung, kidney, and gastrointestinal tract involvem

264 ially accumulated in more organs such as the heart, lung, kidney, etc.

265 escribed adult human subjects who received a heart, lung, kidney, or liver allograft.

266 that Pikfyve is critical in neural tissues, heart, lung, kidney, thymus, and spleen.

267 curement of significantly greater numbers of hearts, lungs, kidneys, pancreases, and intestines, but

268 icated in ischemia/reperfusion injury in the heart, lung, liver, and brain.

269 vascular beds including arteries and veins, heart, lung, liver, and kidney.

270 atest concentrations of rickettsial DNA from heart, lung, liver, and spleen samples when examined by

271 settings and organ transplant types (kidney, heart, lung, liver, pancreas, intestinal, and islet cell

272 MMc was most prevalent in heart, lungs, liver, and blood, but was rarely detected

273 calculated for major organs including brain, heart, lungs, liver, kidneys, spleen, muscle, bone, and

274 The introduction of the heart lung machine more than 50 years ago proved in prin

275 e the number of complications related to the heart-lung machine.

276 scular trees of various organs including the heart, lung, mesentery, muscle, and eye of different spe

277 t study of 8026 patients receiving a kidney, heart, lung, or liver transplant in Norway from 1968 thr

278 icitly coded sepsis, and SOT (kidney, liver, heart, lung, pancreas, or intestine transplants).

279 rs; M-to-F ratio, 17:13; single-to-double-to-heart lung ratio, 5:24:1).

280 rt, liver, pancreas/kidney-pancreas, or lung/heart-lung recipients published between 1981 and 2005 we

281 tissue repair in the liver, nervous system, heart, lung, skeletal muscle, and intestine and illustra

282 as performed to estimate rickettsial load in heart, lung, spleen, and liver tissues of infected mice

283 d according to the International Society for Heart Lung Transplant system for cellular rejection with

284 ibody (HBcAb) status on outcomes of lung and heart-lung transplant recipients.

285 ving PGD using the International Society for Heart & Lung Transplantation (ISHLT)-defined criteria.

286 Heart lung transplantation is a viable treatment option

287 ventilation (MV) can be used as a bridge to heart-lung transplantation (HLT).

288 01), hospitalization for PAH, and/or lung or heart-lung transplantation (OR: 0.442; 95% CI: 0.309 to

289 Both heart-lung transplantation and double-lung transplantati

290 On multivariable analysis, heart-lung transplantation and double-lung transplantati

291 nevertheless, both lung transplantation and heart-lung transplantation candidates in this era enjoye

292 without ECMO (BLTx ventilation) or combined heart-lung transplantation for severe PH.

293 charts of patients undergoing either lung or heart-lung transplantation in a tertiary transplantation

294 linical outcomes for patients after combined heart-lung transplantation in the current era.

295 Patients with CF who underwent lung or heart-lung transplantation in the United States or Unite

296 A rodent heterotopic working heart-lung transplantation model was used for studying a

297 Heart-lung transplantation or bilateral lung transplanta

298 Lung transplantation and heart-lung transplantation represent surgical options fo

299 ungs (n=7) from patients with PAH undergoing heart/lung transplantation and compared with tissue obta

300 s using RV tissue of PAH patients undergoing heart/lung transplantation and nonfailing donors.